Riluzole 1 (Rilutek as marketed by Sanofi) (Fig. 1) is a glutamate antagonist utilized as anti-convulsants and used to treat to amyotrophic lateral sclerosis.52 Riluzole is an activator of the TREK-1 channel and has been used clinically for a long time to treat almost all individuals with amyotrophic lateral sclerosis. Here, KCNK2 is linked to amyotrophic lateral sclerosis.